Member Info for ria20

Https://www.investormeetcompany.com/feedback-plc/register-investor?utm_source=TWITTER&utm_medium=TWITTER&utm_campaign=FDBK

Wow fabulous award and recognition

Enroute...coming in striding forward globally

Never said that paulhall99.....you got the wrong person chump

Maryse Bélanger, interim Chief Operating Officer ("COO") of the Company will step down as COO effective 21 February 2024....this person hasn't got a clue about costs or managing operations

BUY rating given as well

Investor presentation tomorrow....great time to be in

Should get some news this week

With lot more people coming in today

Https://chambers.com/articles/stalicla-secures-usd-17-4m-in-series-b-financing-to-propel-precision-neuro-advancements

HIGHLIGHT15 February 2024

Niederer Kraft Frey advised Stalicla on its series B financing.

Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders has successfully completed the first closing of its series B financing round, securing USD 17.4 million.

Led by SPRIM Global Investments Pte, Ltd, with key participation from core investors, this financing includes a USD 3.8 million credit facility.

The proceeds will be utilised for: (i) preparation of Stalicla’s pioneering precision Autism Spectrum Disorder (ASD) Phase 2 trial – STP1; (ii) the establishment of its STP7 mGluR5 Negative Allosteric Modulator (mGluR5 NAM) platform, including the launch of a Phase III study in Substance Use Disorders (SUDs) slated for 2025, fully supported by the NIH /National Institute on Drug Abuse; (iii) the ramp up of its ongoing bio sampling/patient identification trial STA-B-001 currently enrolling in sites in the USA, Spain and Australia. Alongside these key developments, Stalicla will further strengthen the package supporting its second precision ASD asset, STP2.

Https://www.thearmchairtrader.com/smallcap-round-up-strategic-minerals-evgen-bango-oxford-biodynamics/

Risers on the leaderboard ....buys coming in strong

For RCGH, EVG and FDBK....All primed to breakout

The leaderboard now

Expecting a major breakout upwards in FEB should be an interesting week

Can see a major technical bounce up coming in FEB

Can we have a flurry of buying at close in the top 5 risers today

Glioblastoma, a particularly aggressive form of brain cancer, has been the focus of research by Evgen Pharma PLC. Their SFX-01 product has shown promising activity in glioblastoma cells.

Looking very strong for an afternoon rally and volume has crossed 5.5 million may see a 50 percent rise if we cross 10 million volume at close

Nice morning and rise for SOU AND EVG TODAY......expecting a strong afternoon on both